Compare LMB & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | OBIO |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | 1400 | 86 |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.3M | 473.0M |
| IPO Year | 2014 | 2020 |
| Metric | LMB | OBIO |
|---|---|---|
| Price | $57.02 | $5.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $76.00 | $12.43 |
| AVG Volume (30 Days) | 177.6K | ★ 410.5K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.68 | ★ 33.13 |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $646,804,000.00 | $33,482,000.00 |
| Revenue This Year | $22.56 | N/A |
| Revenue Next Year | $19.28 | $40.42 |
| P/E Ratio | $37.47 | ★ N/A |
| Revenue Growth | 24.68 | ★ 1169.22 |
| 52 Week Low | $40.74 | $3.46 |
| 52 Week High | $114.95 | $6.50 |
| Indicator | LMB | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 54.73 |
| Support Level | $47.02 | $5.54 |
| Resistance Level | $58.99 | $6.49 |
| Average True Range (ATR) | 2.85 | 0.40 |
| MACD | 0.86 | 0.02 |
| Stochastic Oscillator | 83.74 | 70.97 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.